196 related articles for article (PubMed ID: 18555745)
1. Recent advances in bacterial topoisomerase inhibitors.
Bradbury BJ; Pucci MJ
Curr Opin Pharmacol; 2008 Oct; 8(5):574-81. PubMed ID: 18555745
[TBL] [Abstract][Full Text] [Related]
2. [Bacterial type II topoisomerases as targets for antibacterial drugs].
Pietrusiński M; Staczek P
Postepy Biochem; 2006; 52(3):271-82. PubMed ID: 17201062
[TBL] [Abstract][Full Text] [Related]
3. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents.
Mitscher LA
Chem Rev; 2005 Feb; 105(2):559-92. PubMed ID: 15700957
[No Abstract] [Full Text] [Related]
4. Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
Wiener JJ; Gomez L; Venkatesan H; Santillán A; Allison BD; Schwarz KL; Shinde S; Tang L; Hack MD; Morrow BJ; Motley ST; Goldschmidt RM; Shaw KJ; Jones TK; Grice CA
Bioorg Med Chem Lett; 2007 May; 17(10):2718-22. PubMed ID: 17382544
[TBL] [Abstract][Full Text] [Related]
5. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis.
Gomez L; Hack MD; Wu J; Wiener JJ; Venkatesan H; Santillán A; Pippel DJ; Mani N; Morrow BJ; Motley ST; Shaw KJ; Wolin R; Grice CA; Jones TK
Bioorg Med Chem Lett; 2007 May; 17(10):2723-7. PubMed ID: 17368897
[TBL] [Abstract][Full Text] [Related]
6. Old class but new dimethoxy analogue of benzimidazole: a bacterial topoisomerase I inhibitor.
Bansal S; Tawar U; Singh M; Nikravesh A; Good L; Tandon V
Int J Antimicrob Agents; 2010 Feb; 35(2):186-90. PubMed ID: 20006473
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial drug discovery and structure-based design.
Barker JJ
Drug Discov Today; 2006 May; 11(9-10):391-404. PubMed ID: 16635801
[TBL] [Abstract][Full Text] [Related]
8. Functionalized N(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents.
Rajabalian S; Foroumadi A; Shafiee A; Emami S
J Pharm Pharm Sci; 2007; 10(2):153-8. PubMed ID: 17706174
[TBL] [Abstract][Full Text] [Related]
9. Targeting bacterial topoisomerases: how to counter mechanisms of resistance.
Tse-Dinh YC
Future Med Chem; 2016 Jun; 8(10):1085-100. PubMed ID: 27285067
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection.
Ruiz J
J Antimicrob Chemother; 2003 May; 51(5):1109-17. PubMed ID: 12697644
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors.
Tran TP; Ellsworth EL; Sanchez JP; Watson BM; Stier MA; Showalter HD; Domagala JM; Shapiro MA; Joannides ET; Gracheck SJ; Nguyen DQ; Bird P; Yip J; Sharadendu A; Ha C; Ramezani S; Wu X; Singh R
Bioorg Med Chem Lett; 2007 Mar; 17(5):1312-20. PubMed ID: 17196390
[TBL] [Abstract][Full Text] [Related]
12. Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics.
Tse-Dinh YC
Future Med Chem; 2015; 7(4):459-71. PubMed ID: 25875873
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial action of quinolones: from target to network.
Cheng G; Hao H; Dai M; Liu Z; Yuan Z
Eur J Med Chem; 2013 Aug; 66():555-62. PubMed ID: 23528390
[TBL] [Abstract][Full Text] [Related]
14. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
[TBL] [Abstract][Full Text] [Related]
15. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
Charifson PS; Grillot AL; Grossman TH; Parsons JD; Badia M; Bellon S; Deininger DD; Drumm JE; Gross CH; LeTiran A; Liao Y; Mani N; Nicolau DP; Perola E; Ronkin S; Shannon D; Swenson LL; Tang Q; Tessier PR; Tian SK; Trudeau M; Wang T; Wei Y; Zhang H; Stamos D
J Med Chem; 2008 Sep; 51(17):5243-63. PubMed ID: 18690678
[TBL] [Abstract][Full Text] [Related]
16. [The molecular physiological and genetic mechanisms underlying the superb efficacy of quinolones].
Long QX; He Y; Xie JP
Yao Xue Xue Bao; 2012 Aug; 47(8):969-77. PubMed ID: 23162891
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial agents: patent highlights January to June 2003.
Phillips OA
Curr Opin Investig Drugs; 2003 Aug; 4(8):926-36. PubMed ID: 14508876
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial agents: patent highlights January to June 2004.
Phillips OA
Curr Opin Investig Drugs; 2004 Aug; 5(8):799-808. PubMed ID: 15600236
[TBL] [Abstract][Full Text] [Related]
19. [A new generation of broad-spectrum antibacterial chemotherapeutic agents belonging to the group of DNA gyrase inhibitors (derived from pyridine carboxylic acid or quinolines)].
Roy C
Med Clin (Barc); 1985 Jan; 84(3):106-8. PubMed ID: 2983155
[No Abstract] [Full Text] [Related]
20. New agents in development for the treatment of bacterial infections.
Abbanat D; Morrow B; Bush K
Curr Opin Pharmacol; 2008 Oct; 8(5):582-92. PubMed ID: 18761107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
